Future treatment options with capecitabine in solid tumours
- 1 February 2002
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38, 21-25
- https://doi.org/10.1016/s0959-8049(01)00417-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumorsAnnals of Oncology, 2002
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III StudyJournal of Clinical Oncology, 2001
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 2000
- Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5?-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsInternational Journal of Cancer, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prevention of Hypoxia-Induced Apoptosis by the Angiogenic Factor Thymidine PhosphorylaseBiochemical and Biophysical Research Communications, 1998
- Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer XenograftsBiochemical Pharmacology, 1998
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997